By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news originating from Rio de Janeiro, Brazil, by NewsRx correspondents, research stated, "The human induced pluripotent stem cells (hiPSCs) are derived from a direct reprogramming of human somatic cells to a pluripotent stage through ectopic expression of specific transcription factors. These cells have two important properties, which are the self-renewal capacity and the ability to differentiate into any cell type of the human body."
Our news journalists obtained a quote from the research from National Cancer Institute, "So, the discovery of hiPSCs opens new opportunities in biomedical sciences, since these cells may be useful for understanding the mechanisms of diseases in the production of new diseases models, in drug development/drug toxicity tests, gene therapies, and cell replacement therapies. However, the hiPSCs technology has limitations including the potential for the development of genetic and epigenetic abnormalities leading to tumorigenicity. Nowadays, basic research in the hiPSCs field has made progress in the application of new strategies with the aim to enable an efficient production of high-quality of hiPSCs for safety and efficacy, necessary to the future application for clinical practice. In this review, we show the recent advances in hiPSCs' basic research and some potential clinical applications focusing on cancer."
According to the news editors, the research concluded: "We also present the importance of the use of statistical methods to evaluate the possible validation for the hiPSCs for future therapeutic use toward personalized cell therapies."
For more information on this research see: Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Research International, 2013;2013():430290 (see also technology.html">Biotechnology).
The news correspondents report that additional information may be obtained from T.D.E.S. Fernandez, National Cancer Institute (INCA), Bone Marrow Transplantation Center (CEMO), Laboratory Division, 20230-130 Rio de Janeiro, RJ, Brazil. Additional authors for this research include C. de Souza Fernandez and A.L Mencalha.
Keywords for this news article include: Biotechnology, Brazil, Genetics, Oncology, Therapeutics, South America, Rio de Janeiro, Adult Stem Cells, Stem Cell Research, Cancer Gene Therapy, Induced Pluripotent Stem Cells.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC